Insider Transactions in Q2 2024 at Trevi Therapeutics, Inc. (TRVI)
Insider Transaction List (Q2 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 29
2024
|
Thomas Sciascia Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
53,368
-19.93%
|
$106,736
$2.55 P/Share
|
|
May 29
2024
|
Thomas Sciascia Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
59,354
+18.14%
|
$118,708
$2.19 P/Share
|
|
May 22
2024
|
Lisa Delfini Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
4,350
-7.55%
|
$8,700
$2.64 P/Share
|
|
May 22
2024
|
Lisa Delfini Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
16,043
+21.78%
|
$0
$0.51 P/Share
|
|
May 20
2024
|
Jennifer L Good President & CEO |
SELL
Open market or private sale
|
Direct |
25,037
-10.5%
|
$50,074
$2.86 P/Share
|
|
May 20
2024
|
Jennifer L Good President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
25,037
+9.51%
|
$50,074
$2.19 P/Share
|
|
May 10
2024
|
Jennifer L Good President & CEO |
SELL
Open market or private sale
|
Direct |
4,578
-2.1%
|
$9,156
$2.9 P/Share
|
|
May 10
2024
|
Jennifer L Good President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
4,578
+2.06%
|
$9,156
$2.19 P/Share
|